These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17479266)

  • 1. Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
    Lamers CH; Langeveld SC; Groot-van Ruijven CM; Debets R; Sleijfer S; Gratama JW
    Cancer Immunol Immunother; 2007 Dec; 56(12):1875-83. PubMed ID: 17479266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: implications for loss of transgene expression.
    Lamers CH; Gratama JW; Pouw NM; Langeveld SC; Krimpen BA; Kraan J; Stoter G; Debets R
    Hum Gene Ther; 2005 Dec; 16(12):1452-62. PubMed ID: 16390276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma IFN-γ and IL-6 levels correlate with peripheral T-cell numbers but not toxicity in RCC patients treated with CAR T-cells.
    Klaver Y; van Steenbergen SCL; Sleijfer S; Debets R; Lamers CHJ
    Clin Immunol; 2016 Aug; 169():107-113. PubMed ID: 27377533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; van Elzakker P; van Krimpen BA; Gratama JW; Debets R
    Cancer Gene Ther; 2006 May; 13(5):503-9. PubMed ID: 16282986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma.
    Brouwers AH; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    Cancer Biother Radiopharm; 2003 Aug; 18(4):539-47. PubMed ID: 14503948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer.
    Lamers CH; Willemsen RA; Luider BA; Debets R; Bolhuis RL
    Cancer Gene Ther; 2002 Jul; 9(7):613-23. PubMed ID: 12082462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
    Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
    Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy.
    Liu S; Riley J; Rosenberg S; Parkhurst M
    J Immunother; 2006; 29(3):284-93. PubMed ID: 16699371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview.
    Lamers CH; Klaver Y; Gratama JW; Sleijfer S; Debets R
    Biochem Soc Trans; 2016 Jun; 44(3):951-9. PubMed ID: 27284065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts.
    van Dijk J; Uemura H; Beniers AJ; Peelen WP; Zegveld ST; Fleuren GJ; Warnaar SO; Oosterwijk E
    Int J Cancer; 1994 Jan; 56(2):262-8. PubMed ID: 8314310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.
    Zhang Q; Xu J; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Wang Z; Fu Q; Zheng J
    Oncol Rep; 2018 Dec; 40(6):3714-3724. PubMed ID: 30272343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo flow cytometry determination of intracytoplasmic expression of IL-2, IL-6, IFN-gamma, and TNF-alpha in monocytes and T lymphocytes, in chronic hemodialysis patients.
    Rostaing L; Peres C; Tkaczuk J; Charlet JP; Bories P; Durand D; Ohayon E; de Préval C; Abbal M
    Am J Nephrol; 2000; 20(1):18-26. PubMed ID: 10644863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of immunotherapy (IL2 + LAK + inhibition of prostaglandin synthesis) on peripheral blood immune parameters and in vitro cytokine production in metastatic renal cell carcinoma.
    Kleinknecht S; Bichler KH; Strohmaier WL
    Urol Int; 1993; 50(3):121-8. PubMed ID: 8465478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
    Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
    J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
    Lamers CH; Sleijfer S; van Steenbergen S; van Elzakker P; van Krimpen B; Groot C; Vulto A; den Bakker M; Oosterwijk E; Debets R; Gratama JW
    Mol Ther; 2013 Apr; 21(4):904-12. PubMed ID: 23423337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.